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AbsTrACT
Objectives To quantify the availability of authorised, 
age- appropriate paediatric medicines in clinical practice 
in the Netherlands and to identify gaps by assessing 
dispensing practice in a paediatric hospital.
Methods The availability of age- appropriate 
formulations was assessed by conducting a survey on 
the use of pharmacy compounded medicines among 
the paediatric hospitals in the Netherlands, and by 
analysing dispensing data of oral medication from the 
inpatient pharmacy of the largest paediatric hospital 
in the Netherlands. The age- appropriateness of the 
dispensed formulations was assessed on two aspects: 
dose- capability and acceptability. Liquid drug products 
that are unsuitable due to the presence of potentially 
harmful excipients, were identified based on the dosage 
in clinical practice.
results For 129 out of 139 drug substances 
included in the survey (93%), at least one of the eight 
respondents stated to use a pharmacy compounded 
product to meet the needs of their paediatric patients. 
The age- appropriateness of medicines dispensed from 
the inpatient pharmacy increased with age, and was 
higher for non- intensive care unit (ICU) patients than 
for ICU patients. We identified 15 drug products causing 
excipient exposure above the European Medicines 
Agency- recommended values.
Conclusions This study confirms there is still a large 
need for age- appropriate formulations in daily clinical 
practice. Pharmacy compounding for paediatric patients 
remains essential for many indications. The need for 
potentially harmful excipients in compounded products 
should be critically assessed.
InTrOduCTIOn
Drug development for children has long been a 
neglected area compared with adult drug develop-
ment. Low prevalence of disease and the resulting 
low return on investment, together with ethical and 
practical barriers, have not been providing enough 
incentives for pharmaceutical corporations to 
invest time and resources into bringing appropri-
ately tested paediatric medicines to the market. It 
was recognised that specific legislation was needed 
to address this issue. Following the example of the 
US Best Pharmaceuticals for Children Act, the EU 
Paediatric Regulation (EC)1 No 1901/2006 was 
adopted in December 2006.1
Since the introduction of the Paediatric Regula-
tion, many initiatives have been taken to improve 
the availability of paediatric drug formulations. 
New dosage forms such as dispersible films and 
multiparticulates (eg, sprinkles, mini- tablets) have 
been developed,2 and during the years 2007–2016, 
over 260 new medicines have been authorised in 
the EU for use in children, which is regarded as 
the success of the Paediatric Regulation.3 Unfortu-
nately, we also see that the paediatric use marketing 
authorisation (PUMA) delivered a very limited 
number of age- appropriate paediatric formula-
tions for off- patent drugs, with only four PUMAs 
granted during the first 10 years of the Paediatric 
Regulation.4
Looking at the European Medicines Agency 
(EMA) priority list of off- patent medicinal products,5 
and the inventory of needs for paediatric medicines,6 
a discrepancy emerges between the availability of 
marketed paediatric medicines and the medicines 
needed in daily practice. Within the Netherlands, the 
limited commercial availability of authorised medi-
cines for children has previously been recognised by 
van Riet- Nales et al.7 These authors compared dosing 
information for use in children from a national Medi-
cines Compendium (Informatorium Medicamen-
torum) with the official indications in the Summary 
of Product Characteristics (SmPC), and found a 48% 
overall availability of authorised medicines for chil-
dren. Furthermore, the age- appropriateness of the 
formulation, as well as the presence of potentially 
harmful excipients were assessed, confirming a lag 
in pharmacotherapeutic treatment options compared 
with adults. However, this study did not involve the 
need in clinical practice in its design.
The absence of age- appropriate, authorised and 
commercially available dosage forms is forcing 
pharmacists to compound drugs, or caregivers to 
manipulate adult formulations before administra-
tion. Individual compounding and manipulation of 
medicines can be costly and time- consuming, but 
most importantly carry risks for the patient. Exam-
ples of safety issues linked to compounding include 
decreased bioavailability of a tacrolimus suspen-
sion,8 and a 10- fold dosing error of spironolac-
tone due to the availability of different strengths.9 
Manipulations such as crushing of tablets can lead 
to loss of controlled release properties, or loss of 
drug substance.10 Furthermore, splitting of both 
scored and unscored tablets can lead to dose inac-
curacies, and splitting devices are not necessarily 
more accurate than splitting by hand.11 12 Another 
important disadvantage of the use of unstandardised 
compounded medicines is the absence of clinical 
decision support with electronic prescribing.
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Table 1 Additional suitability criteria for paediatric oral dosage 
forms aside from the EMA matrix7
Tablets A single dose may involve two tablets at the maximum
A single dose may involve a halved tablet, if 1) the tablet contains a score 
line; 2) the SmPC does not state that the scoring line is for esthetical 
reasons only; 3) the SPC does not state that the tablet may only be broken 
to facilitate the intake of the full dose.
Oral liquid 
preparations
The maximum dosing volume is 5 mL for children aged below 5 years.
The maximum dosing is 10 mL for children aged from 5 to 10 years.
The minimum single dosing is 0.2 mL.
SmPC, Summary of Product Characteristics.
Regardless of the authorisation status, a lot of medicines 
dispensed to paediatric patients are not age- appropriate, either 
because of unacceptability of the dosage form to the patient or 
because of incapability to provide the correct dose.7 The accept-
ability of different dosage forms to paediatric patients has been 
summarised in the ‘Reflection paper on formulations of choice 
for the paediatric population’ by the EMA.13 It provides a matrix 
proposing applicability and acceptability of different dosage 
forms in specific age groups, based on a limited amount of 
evidence. For this reason, it was presented as a rough guide, and 
not an evidence- based recommendation for the development 
of dosage forms. Since then, acceptability studies of different 
dosage forms have become available, but the methodologies 
have not been standardised, and for some age groups and dosage 
forms, no consensus has been obtained.14
One aspect determining the age- appropriateness of medicines 
is the presence of potentially harmful excipients. Excipients 
are generally considered to be pharmacologically inactive, but 
they pose a risk for patients with immature metabolic pathways 
and organ systems. For several of them, the EMA has published 
reflection papers or questions and answers, addressing the 
safety issues with use in paediatric medicines. These potentially 
harmful excipients are frequently used in liquid formulations, 
but their harmfulness is relative to exposure and patient char-
acteristics. Excipient exposure in preterm infants and neonates 
has previously been assessed for several substances.15–17 These 
studies showed that a lot of drug products used in paediatrics are 
possibly unsuitable due to their excipients, but to date, this has 
only been evaluated for the youngest patients.
In summary, there is still a limited availability of commercial 
and age- appropriate paediatric medicines, but the magnitude of 
the problem in clinical practice has not been determined. The 
aim of this research was to quantify the availability of commer-
cial, age- appropriate paediatric medicines and to identify gaps. 
In order to achieve this aim, we made use of different strategies 
and datasets and in contrast to earlier work, this study specifi-
cally focuses on daily clinical practice.
The availability of commercial drug products, restricted to 
oral medication, was assessed using two datasets: 1) a survey 
on the use of pharmacy compounded (non- commercial) medi-
cines among the paediatric hospitals in the Netherlands and 
2) dispensing data from the inpatient pharmacy of the largest 
paediatric hospital in the Netherlands. Subsequently, the age- 
appropriateness of the dispensed oral formulations was assessed 
according to EMA acceptability guidance and additional criteria 
previously applied by van Riet- Nales et al.7 Finally, we identified 
liquid drug products that are unsuitable due to the presence of 
potentially harmful excipients, based on the extent of exposure 
in clinical practice.
MeThOds
Availability of paediatric medicines in the netherlands
In 2016, a survey was conducted among the 11 Dutch academic 
and teaching paediatric hospitals, to identify the use of phar-
macy compounded medicines for paediatric patients in the 
Netherlands. For the survey, we established a list of drugs of 
interest based on the existing monographs of the Dutch Paedi-
atric Formulary.18 19 Based on route of administration (oral), 
unavailability of a commercial oral liquid dosage form, and the 
absence of an equivalent therapeutic alternative (eg, pantopra-
zole and omeprazole), we included 139 drug substances (online 
supplementary appendix 1) in the survey. Respondents were 
asked to confirm if 1) the drug was applied for their patients, 2) 
a commercially available product was able to meet the needs of 
their patients and 3) they made use of a pharmacy compounded 
product. Furthermore, we asked them to supplement the list 
with any products they thought were missing. The results were 
subsequently compared with the EMA inventory of paediatric 
needs.
To supplement the qualitative data collected in the survey, 
we used the prescription and dispensing data of the Erasmus 
MC- Sophia Children’s Hospital to quantify for which age groups 
dispensing of pharmacy compounded, non- commercial products 
was most prevalent. In this dataset, non- Dutch Paediatric Formu-
lary medicines were also included. Age categories were defined 
according to the guideline on clinical investigation of medicinal 
products in the paediatric population,20 and all patients admitted 
to the neonatal intensive care unit (NICU) were categorised as 
preterm neonates. All electronically prescribed medication 
orders, for patients admitted to the paediatric intensive care 
unit (PICU), NICU or the remaining non- ICU units (surgical, 
oncology and general wards) were evaluated at start of treat-
ment. The electronic prescription data were corrected when the 
dispensed dosage form deviated from the prescription. A MSc 
pharmacy student prospectively collected these discrepancies at 
the inpatient pharmacy on weekdays over a period of 10 weeks 
during the autumn of 2016.
Age-appropriateness of paediatric formulations dispensed 
from the inpatient pharmacy
In addition to the availability of commercial drug products, 
we evaluated the dose- capability (the capability to deliver the 
correct dose) and age- appropriateness of all oral medication 
dispensed from the pharmacy according the criteria previ-
ously applied by van Riet- Nales et al,7 using the dispensing 
dataset described above. In this dataset, we also included injec-
tions fluids dispensed for oral administration. To assess dose- 
capability, manipulations to the dispensed product required to 
obtain the correct dose, such as tablet splitting, were verified 
with the SmPC. Age- appropriateness of the formulation was 
determined using the acceptability matrix of the EMA reflection 
paper,13 supplemented with the criteria displayed in table 1. The 
EMA matrix, combining different age groups, routes of admin-
istration and dosage forms, assigns levels of either applicability 
(younger ages) or acceptability (higher ages) ranging from 1: not 
applicable/not acceptable to 5: best and preferred applicability/
dosage form of choice. We considered a value of 4 or 5 to repre-
sent sufficient suitability. Different from van Riet- Nales et al, we 
considered capsules that may be opened, and tablets that may 
be pulverised according to the SmPC, to be suitable for children 
from the age of 2 years, instead of the age of 1 month.
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Table 2 Excipients and cut- off values for safe exposure per age 
group, derived from EMA publications
excipient Age Limit explanation
Ethanol21 <2 years Avoid
  2–5 years 6 mg/kg Suggested limit in 
medicines based on a BAC 
rise of 0.01 g/L.
  ≥6 years 75 mg/kg Suggested limit in 
medicines based on a BAC 
rise of 0.125 g/L.
Propylene glycol26 Neonates 1 mg/kg/day Considered to be safe 
and with no noticeable 
effects whatever the 
duration and the route of 
administration.*
  1 month–4 years 50 mg/kg/day
  ≥5 years 500 mg/kg/day
Benzyl alcohol29 Preterms and 
neonates
Not recommended
Propyl paraben30 Any 2 mg/kg/day Permitted daily exposure 
according to the method 
outlined in ICH Q3C.
*With the exception of inhalation.
BAC, blood alcohol concentration; EMA, European Medicines Agency; ICH Q3C, International 
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals 
for Human Use guideline Q3C.
Table 3 Most frequently used compounded drugs across paediatric 
hospitals in the Netherlands
drug
Therapeutic class according 
to eMA needs for paediatric 
medicines
Formulation 
requirement according 
to eMA needs for 
paediatric medicines
Acetazolamide Neurology No
Amlodipine Nephro- urology Yes
Caffeine Respiratory No
Carvedilol Cardiovascular Yes
Chloral hydrate Neurology/Psychiatry Yes
Clobazam Neurology No
Clonidine Cardiovascular Yes
Dexamethasone Endocrinology No
Enalapril Nephro- urology Yes
Furosemide Nephro- urology No
Hydrochlorothiazide Nephro- urology Yes
Hydrocortisone Endocrinology/Immunology Yes
Labetalol Cardiovascular No
Lorazepam Neurology/Psychiatry Yes
Methadone Pain No
Midazolam Anaesthesiology/Psychiatry Yes
Nifedipine Nephro- urology Yes
Pancreatine Gastroenterology Yes
Phenobarbital Neurology Yes
Phenytoin Neurology No
Prednisolone Rheumatology/Immunology Yes
Propranolol Cardiovascular No
Sildenafil Cardiovascular No
Sodium benzoate Metabolic disorders No
Sotalol (hydrochloride) Cardiovascular Yes
Spironolactone Nephro- urology No
Tacrolimus Immunology No
Topiramate Neurology/Psychiatry Yes
EMA, European Medicines Agency.
excipients in paediatric formulations
To identify liquid drug products that are unsuitable due to the 
presence of potentially harmful excipients, four commonly used 
excipients with known risks were selected: ethanol, propylene 
glycol (PG), benzyl alcohol and propyl paraben. To allow for 
comparison with previously published work, non- oral formula-
tions were also included. Cut- off values for maximum excipient 
exposure considered to be suitable for a certain age group were 
retrieved from EMA publications and are summarised in table 2. 
As there are no daily limits published for ethanol, we interpreted 
the single dose limits from the current draft EMA document on 
ethanol as daily limit.21 To quantify the exposure of our patients 
to potentially harmful excipients, we studied the actual dosages 
and drug formulations administered at the paediatric wards, also 
including parenteral and rectal formulations. Information on the 
composition of the formulations was retrieved from the SmPC 
or via direct communication with the marketing authorisation 
holder or manufacturer. The dataset for the analysis contained all 
ongoing medication orders for each single day in February 2017 
and was obtained from the electronic prescribing systems of the 
Erasmus MC- Sophia Children’s Hospital. The daily adminis-
tered amounts of excipients were calculated for each individual 
patient and compared with the recommended values for safe 
exposure. If patients were on multiple medicines simultaneously, 
this was factored into the daily exposure calculation. After iden-
tifying patients with potentially harmful exposure, we calculated 
the median (range) exposure per product and age group.
data analysis
Descriptive statistics were performed with Microsoft Excel 2010.
resuLTs
Availability of paediatric medicines in the netherlands
Out of the 11 academic and teaching paediatric hospitals that were 
approached, 8 responded and filled out the questionnaire. The 
survey revealed that for 129 out of 139 drug substances (93%), 
at least one of the eight respondents stated that a compounded 
product was needed to meet the needs of their paediatric patient. 
Table 3 displays all medicines for which at least five respondents 
stated to use a compounded drug. For 13 of these 28 drugs 
(46%), the EMA inventory of paediatric needs does not state 
the need for an age- appropriate formulation. Importation from 
other countries occurred for 25 drug substances (18%), most 
cited were valganciclovir (four respondents), and doxapram, 
nitazoxanide and alimemazine (two respondents).
dispensing of commercial products from the inpatient 
pharmacy
Over the 10- week study period during the autumn of 2016, 
2274 oral medication orders were evaluated for a total of 437 
patients. Our data show that the use of commercially available 
drugs was lowest in preterm neonates (193/418 prescriptions, 
46%) and neonates at the PICU (33/80 prescriptions, 41%) and 
non- ICU wards (20/54 prescriptions, 37%). Figure 1 displays the 
percentage of commercial products dispensed per age group, for 
ICU and non- ICU patients.
Age-appropriateness of paediatric formulations dispensed 
from the inpatient pharmacy
Results from the dose- capability and age- appropriateness assess-
ment depicted in figure 2 revealed that only 402/601 (67%) of 
dispensed oral formulations for the PICU were considered suitable 
for the patient according to the set criteria. For the non- ICU wards 
this number was higher, with 1047/1255 (83%) dispensed oral 
formulations regarded as suitable. For the NICU, all 418 dispensed 
oral formulations were considered unsuitable, as the EMA dosage 
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Figure 1 Prevalence of dispensing of commercial oral drug products per 
age category.
Figure 2 Suitability of oral dosage forms dispensed from the inpatient 
pharmacy.
form matrix considers all oral dosage forms to be ‘applicable with 
problems’ in preterm new- born infants. Outside of the NICU, 
dispensing of unsuitable products was most prevalent in neonates 
and infants at the ICU, with a percentage of 42% in both groups. 
This was mainly the result from dispensing of solid dosage forms, 
which are considered unsuitable according to the EMA matrix up 
to an age of 2 years. The percentage of dispensed suitable formula-
tions increased with age, up to 94% in adolescent ICU patients and 
88% in adolescent non- ICU patients.
excipients in paediatric formulations
For the identification of unsuitable drug products due to the pres-
ence of potentially harmful excipients, we used a second dataset 
with prescription data from the inpatient wards of the Sophia 
Children’s Hospital from February 2017. A total of 383 unique 
patients were admitted and received medication during the study 
period. From a total of 14 449 medication orders, we identified 
40 drug products containing the selected excipients. The cut- off 
values for excipient exposure were surpassed in 22/33 (67%) of 
NICU patients, 18/77 (23%) of PICU patients and 16/311 (5%) of 
non- ICU patients. Exposure sometimes continued over multiple 
days (median 6, range 1–15 days), and was most frequent with 
the use of caffeine oral liquid (16 patients, PG), nystatin suspen-
sion (10 patients, ethanol) and alprostadil infusion (9 patients, 
ethanol), which are all administered for prolonged periods if 
necessary. For PG, the highest daily exposure was observed for 
diclofenac intravenous, lorazepam intravenous and itraconazole 
oral liquid.
In total, we identified 15 products that caused excipient expo-
sure above the recommended values, as displayed in table 4. Five 
of these products were pharmacy compounded, non- commercial 
liquids. Propranolol, furosemide and hydrochlorothiazide 
liquids were prepared according to the Formulary of Dutch 
Pharmacists.22 PG in these products comes from a concentrated 
methyl paraben solution (15% m/v), used to process the preser-
vative. No benzyl alcohol administration above cut- off value was 
observed during our study period.
dIsCussIOn
The results from this study show that 10 years after the intro-
duction of the Paediatric Regulation, there is still a large need 
for age- appropriate formulations in daily clinical practice. The 
largest need was observed for the youngest age groups from 
neonates to infants and toddlers, and the need was higher at ICU 
wards compared with non- ICU wards.
The widespread use of pharmacy compounded products 
confirms that the currently available commercial products do 
not meet the needs of paediatric patients. Almost half of the 
commonly used compounded products in the Netherlands 
were not included in the EMA inventory of paediatric needs. 
This inventory stems from a report adopted by the Paediatric 
Committee in December 2010, on the survey of all paediatric 
uses of medicines in Europe. Interestingly, for the Netherlands, 
only outpatient data were provided for the survey by the Paedi-
atric Committee,23 which may be an explanation for the discrep-
ancies between the inventory and our results.
Individual compounding carries risks for the patient. In the 
Netherlands, to mitigate these risks, the Formulary of Dutch 
Pharmacists aims to standardise compounding and increase 
the quality. This formulary contains over 160 standardised 
monographs for extemporaneous formulations, and for each 
product, quality and shelf- life data are available. Many of these 
unauthorised products are produced under Good Manufac-
turing Practice(GMP) conditions in large compounding phar-
macies, to obtain medicines of high pharmaceutical quality. 
Within hospital affiliated GMP facilities, they can be produced 
at relatively low cost, as there is no profit motive. The Dutch 
drug laws ensure that once a commercial product is marketed, 
extemporaneous products can no longer be supplied to other 
pharmacies. Compounding of Officinal Formula, meaning any 
medicinal product which is prepared in a pharmacy in accor-
dance with the prescriptions of a pharmacopoeia and is intended 
to be supplied directly to the patients served by the pharmacy 
in question, is however still allowed. On a European level, in 
November 2011, The European Directorate for the Quality of 
Medicines & HealthCare (EDQM) has commenced to generate 
a pan- European paediatric formulary, to improve access to 
suitable and age- appropriate formulations. This formulary will 
contain monographs of extemporaneous formulations based on 
the best approaches currently available in national or regional 
formularies within Europe.24
Analysis of our own dispensing data showed that (preterm) 
neonates and infants were most likely to receive non- commercial, 
compounded formulations. This can be expected as older chil-
dren are more likely to be able to receive the correct dose using 
(manipulated) adult dosage forms. However, the dispensing of a 
commercial product does not mean that the dosage form is suit-
able for the patient. When comparing our results with the results 
of van Riet- Nales et al, who conducted their research 7 years 
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Table 4 Drug products causing excipient exposure above the cut- off values, the number of patients exposed and the corresponding median (range) 
daily exposure per product and age group
Generic drug name brand drug name
route of 
administration
drug 
concentration
ethanol 
concentration 
(mg/mL) Age group no. of patients
ethanol (mg/kg/
day) Median range
Alprostadil Prostin VR Intravenous 0.5 mg/mL 790 Neonates 7 18.7 14.0–80.6
          Infants and 
toddlers
2 64.8 14.4–144
Amphotericin B Fungizone Per os 100 mg/mL 4.21 Neonates 3 0.9 0.8–1.0
          Infants and 
toddlers
6 0.6 0.4–2.1
Clemastine Tavegyl Intravenous 1 mg/mL 70 Infants and 
toddlers
3 6.3 6.2–6.4
Diazepam Rectiole Rectal 2 mg/mL 100 Infants and 
toddlers
2 1.8 1.8–1.9
Digoxin Lanoxin PG Elixer Per os 0.05 mg/mL 81.7 Infants and 
toddlers
1 5.4
Nystatin Labaz Per os 100 000 U/mL 7.9 Preterms 7 23.8 9.7–48.9
          Infants and 
toddlers
3 7.8 1.9–11.8
        Propylene 
glycol 
concentration 
(mg/mL)
  Propylene glycol 
(mg/kg/day) 
Median
Caffeine Non- commercial liquid Per os 10 mg/mL 9.1 Preterms 16 4.8 4.3–9.2
          Neonates 4 4.6 3.3–9.5
Diclofenac Generic Intravenous 25 mg/mL 200 Infants and 
toddlers
3 72.8 70.6–81.0
Furosemide Non- commercial liquid Per os 2 mg/mL 9.1 Preterms 4 4.8 3.9–5.6
          Neonates 7 13.1 5.7–26.4
Hydrochlorothiazide Non- commercial liquid Per os 0.5 mg/mL 9.1 Preterms 4 8.0 6.9–16.4
Itraconazole Trisporal liquid Per os 10 mg/mL 103.6 Children 1 52.1
Lorazepam Temesta Intravenous 4 mg/mL 823 Infants and 
toddlers
2 82.3 64.6–123.5
Potassium chloride Non- commercial liquid Per os 1 mmol/mL 6.1 Neonates 1 13.3
Propranolol Non- commercial liquid Per os 1 mg/mL 2.275 Preterms 1 4.4 2.5–5.1
        Propyl paraben 
concentration 
(mg/mL)
  Propyl paraben 
(mg/kg/day) 
Median
Paracetamol DARO liquid Per os 24 mg/mL 0.56 Infants and 
toddlers
3 2.1 2.0–2.1
          Children 1 2.1 2.0–2.1
earlier and from a regulatory perspective, the percentage of 
authorised and dose- capable medicines with an age- appropriate 
formulation was very similar. With our study, these results can 
now be confirmed from a clinical perspective. Unfortunately, we 
must conclude that progress has been limited.
In the assessment of excipient exposure from liquid products, 
we found that possible harmful exposure was not limited to only 
NICU patients, but was relevant in children up to the age of 
4 years.
Whittaker et al16 observed ethanol exposure in preterm 
infants up to 1.8 mL of ethanol per week (1422 mg), uncor-
rected for weight. In our NICU population ethanol exposure 
was mainly caused by nystatin treatment, which has a standard 
dosing schedule of 1 mL four times daily, leading to a cumula-
tive exposure of 0.28 mL of ethanol per week (221 mg), which is 
significantly lower. A follow- up study by the same group found 
that ethanol concentration in neonates were not elevated after 
exposure through medication, but they did find elevated levels 
of acetaldehyde.17 This supports the concept that neonates have 
minimal systemic exposure to ethanol after enteral administra-
tion at the studied dose levels, due to a first- pass effects, but 
exposure to acetaldehyde might be just as relevant. At the PICU, 
alprostadil infusions led to ethanol exposure as high as 0.18 mL/
kg/day in infants and toddlers, which is equivalent to 1 (NL) unit 
of alcohol for a 70 kg adult. The fact that it is administered intra-
venously, also means that there is no first- pass effect to decrease 
the systemic exposure. Currently, there is no alternative for this 
treatment, but fortunately the duration of therapy is limited. 
Even though the effect of long- term exposure to low levels of 
ethanol in medicines on the health and development of children 
has not been evaluated, there is broad consensus among medi-
cines agencies that exposure in children should be minimised.21
The levels of PG exposure we observed in our population 
were relatively low compared with the exposure reported by 
Whittaker et al. In preterms and neonates, the WHO accept-
able daily intake limit of 25 mg kg-116 was not exceeded, but the 
EMA limit in neonates of 1 mg kg-1 day-1 was. In infants, toddlers 
and children, we identified three products that produced signif-
icant exposure; diclofenac and lorazepam intravenous fluid, and 
itraconazole liquid. Especially the latter is concerning, as treat-
ment often continues over several months, and a therapeutic 
alternative is not available.
Compared with the results reported by Akinmboni et al,25 
excipient exposure in our NICU patients was lower (67% vs 
98%) compared with exposure in their study population of 
106 low birth weight preterm neonates. It is notable that they 
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observed eight different products containing benzyl alcohol, 
although over a study period of a full year, opposed to zero 
products in our 1 month study period. In total, they identified 
19 products containing unwanted excipients at the NICU alone, 
compared with only 5 in our NICU population. This differ-
ence can be explained by substitution of unfavourable products 
with pharmacy compounded alternatives, free of unwanted 
excipients, one example being ranitidine oral liquid, which is 
compounded in an ethanol- free formulation with a concentra-
tion of 15 mg/mL.
Overall, excipient exposure in our patients was lower 
compared with other studies. This is probably the result of the 
awareness within pharmacy compounding for potential harmful 
excipients. Nevertheless, we identified non- essential products 
that we should either try to avoid or substitute, and essential 
medicines in need of improvement. On the other hand, it is 
important to note that the cut- off values used in this study should 
not be interpreted as absolute limits. It should be kept in mind 
that higher doses may be administered when justified.26 The 
suitability assessment in this study focused on four commonly 
used solvents and preservatives, but there are more excipients 
with reports of possible toxicity in paediatric patients, including 
sweeteners, solubilising agents and flavourings.27 28
strengths and limitations
The major strength of this study was the use of clinical dispensing 
data, which enabled the identification of relevant needs in 
different age groups and level of care settings. Also, we included 
the entire age range of paediatric patients in our research. The 
suitability assessment revealed that at least one- third of dispensed 
oral dosage forms for the PICU and one- sixth of non- ICU oral 
medication were not age- appropriate. These results must be 
interpreted with caution, as the acceptability matrix from the 
EMA reflection paper was based on sparse evidence. If more 
recent evidence on acceptability of mini- tablets and multipar-
ticulate dosage forms would have been included in the matrix, 
the results might have differed slightly. Unfortunately, rather 
few of those kinds of dosage forms are actually available. Also, 
even though 3 years have passed since data collection took place, 
none of the most frequently compounded products presented in 
the results have been replaced with a commercial formulation. 
Other aspects that might decrease the ability of patients to take 
solid dosage forms, such as sedation and/or tube feeding, were 
not considered, but almost all of the solid dosage forms that were 
found suitable for children and adolescents can be administered 
through a feeding tube after manipulation, which means that 
the results would largely remain the same. Palatability, which is 
an important component of acceptability, was not considered in 
the assessment, as it is unknown for most drugs. Future research 
should focus on generating evidence on patient preference and 
acceptability of dosage forms, to further assist the development 
of suitable paediatric drug products. Data collection took place 
during a specific time of the year, which means that we could 
have missed some medications that are seasonally dependent.
COnCLusIOn
This study confirms there is still a large need for age- appropriate 
formulations in daily clinical practice, despite the successes of 
the Paediatric Regulation. Pharmacy compounding for paediatric 
patients remains essential for many indications, and the EDQM 
paediatric formulary is therefore warranted. Concomitantly, efforts 
should be made to reduce the exposure to potentially harmful 
excipients, by avoiding or substituting non- essential medicines, and 
improving the composition of essential medicines.
What this paper adds
What is already known on this subject
 ► The paediatric use marketing authorisation has delivered 
a very limited number of age- appropriate paediatric 
formulations for off- patent drugs.
 ► There is still a limited availability of commercial and age- 
appropriate paediatric medicines.
What this study adds
 ► Using a survey among paediatric hospitals in the Netherlands, 
we identified the most commonly compounded paediatric 
medicines.
 ► We identified liquid drug products that are unsuitable due 
to the presence of potentially harmful excipients by linking 
excipient contents to actual prescribed dosages.
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